Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor T cell (AlloCAR) therapies for cancer. Allogeneic therapies use healthy donor cells, which are engineered to target and destroy cancer cells, offering a promising alternative to traditional autologous CAR T therapies that use a patient's own cells. The company aims to revolutionize cancer treatment by providing off-the-shelf, on-demand therapies that are scalable and efficient, reducing product variability and ancillary costs.

Allogene operates in the biotechnology and healthcare market, primarily serving patients with various types of cancer. The company's business model revolves around the research, development, and commercialization of its proprietary AlloCAR therapies. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of approved therapies.

The company boasts a highly experienced management team, including pioneers in CAR T cell therapy, and employs around 200 individuals. Approximately 50% of the senior leadership team and the entire organization identify as female, highlighting Allogene's commitment to diversity and inclusion.

Allogene's innovative approach includes multiplex gene engineering, gene editing capabilities, and a proprietary lymphodepletion platform. The company's state-of-the-art manufacturing processes allow for the potential treatment of up to 100 patients from a single manufacturing run, making it a cost-effective solution.

Keywords: Allogeneic, CAR T cell, cancer therapy, biotechnology, gene editing, lymphodepletion, scalable manufacturing, on-demand treatment, clinical trials, immunotherapy.